A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT03026166. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).
Study identification
- NCT ID
- NCT03026166
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 42 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2017
- Primary completion
- Jul 2, 2019
- Completion
- Jul 2, 2019
- Last update posted
- Jul 16, 2020
2017 – 2019
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ucsd /Id# 161030 | La Jolla | California | 92093 | — |
| Florida Hospital /ID# 161017 | Orlando | Florida | 32803 | — |
| University Cancer & Blood Cent /ID# 161028 | Athens | Georgia | 30607 | — |
| University of Chicago /ID# 161006 | Chicago | Illinois | 60637-1443 | — |
| The University of Kansas Clini /ID# 162915 | Fairway | Kansas | 66205 | — |
| Washington University-School of Medicine /ID# 161011 | St Louis | Missouri | 63110 | — |
| Rutgers Cancer Institute of NJ /ID# 161032 | New Brunswick | New Jersey | 08903 | — |
| Memorial Sloan Kettering Cancer Center /ID# 161010 | New York | New York | 10065-6007 | — |
| Duke University Medical Center /ID# 161009 | Durham | North Carolina | 27710-3000 | — |
| Oregon Health and Science University /ID# 161029 | Portland | Oregon | 97239 | — |
| Medical University of South Carolina /ID# 161007 | Charleston | South Carolina | 29425 | — |
| Tennessee Oncology, PLLC /ID# 161012 | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Med Ctr /ID# 162916 | Nashville | Tennessee | 37232-6307 | — |
| Virginia Cancer Institute /ID# 161025 | Richmond | Virginia | 23230 | — |
| University of Wisconsin Clinic /ID# 161013 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03026166, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 16, 2020 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03026166 live on ClinicalTrials.gov.